The GHK-Cu injection reaction the guides never documented

GHK-Cu is the copper one. The molecule is a three-amino-acid chain, glycine-histidine-lysine, bound to a copper ion, first described by Loren Pickart in the mid-1970s. The copper is not incidental. It is the reason a real vial is blue, and it is the prime suspect in the injection-site problem this post is about.

Here is what the community keeps reporting and cannot resolve: injection-site reactions, stinging, marks, and lumps that people say do not always clear when they stop. The reports are anecdotal, they are tracked nowhere, and they are why this topic surfaced as a signal in the first place. What follows is what the evidence actually supports, and where it runs out.

The two fixes the community reaches for

Max dilution. The standard move is to reconstitute GHK-Cu in as much bacteriostatic water as the vial and your dosing allow, because more dilution reduces the sting on injection. That part is real and widely repeated. What it does not do is anything documented for a reaction that lingers after you stop. Less sting going in is not the same as less tissue reaction over time, and nobody has shown the second follows from the first.

Zinc. Copper and zinc compete in the body, so the folk logic runs that zinc supplementation offsets the copper you are injecting. It sounds reasonable. It is also undocumented for this specific problem. There is no data showing oral zinc resolves or prevents a local reaction to an injected copper peptide, and treating it as a fix is guesswork dressed as a protocol.

Both fixes target the sting, not the thing people are actually worried about.

Why GHK-Cu is worse-documented than BPC-157 or TB-500

This is the real story, and it is a gap, not a scandal.

The moderate human evidence for GHK-Cu is almost entirely topical. Roughly thirty to forty years of skin studies: collagen remodeling, texture, wound repair. Injectable GHK-Cu has no good human data at all. The compound most people met through skincare has essentially no clinical record for the route they are now injecting.

Compare the peptides in the "Wolverine stack." BPC-157 and TB-500 also run on weak, mostly animal data, but they carry a voluminous anecdotal injection record: years of community reports on doses, sites, and reactions. GHK-Cu injected does not have that depth of even informal documentation. It is a skincare molecule the injectable community adopted faster than anyone characterized what it does under the skin.

Regulation is behind too. When the FDA's compounding committee works through peptides, GHK-Cu is not in the first round with BPC-157 and TB-500. It is expected only in a later round. Less clinical attention, less regulatory attention, and a copper payload going subcutaneously. That combination is why a persistent local reaction is at least plausible, and why no one can tell you how common it is.

What actually holds up

A few things are grounded enough to act on.

Real GHK-Cu is blue. If a vial or a topical is white, it is not GHK-Cu, it is a different peptide, and a sourcing problem becomes a more likely explanation for a bad reaction than the compound itself. Blue alone is not proof (copper can fall out of the complex), but white is a hard no.

The one caution the clinical sources are direct about: do not self-inject GHK-Cu, especially into the face, if you are not trained. There is no good human injectable data to lean on, and the face is the worst place to find that out.

And a reaction that outlasts the protocol is not something to self-manage with more dilution and a zinc capsule. It is the point to bring an actual clinician in. The peptide community is good at sharing what worked. It has no mechanism for tracking what left a mark, which is why "does this go away" has no crowd answer.

The honest version

GHK-Cu injected is a compound with real topical evidence and almost no injectable evidence, adopted ahead of its own documentation. Max dilution reduces the sting and nothing else that is proven. Zinc is a hypothesis. The persistent-reaction reports are real enough to take seriously and too thin to explain, and the copper in the molecule is the likely reason both of those are true at once.

If you are still deciding whether to trust a given vial or supplier, that part is tractable. Start with how to vet a source, check whether a lab test is worth paying for, and read what a peptide purity number actually buys you. More of how we think about protocols and sourcing is on the blog feed.